SORRENTO THERAPEUTICS, INC. Form 8-K (Dec. 6, 2021)

Summary

Current report on Form 8-K for an event dated December 6, 2021, filed by Sorrento Therapeutics, Inc. Under Item 7.01 (Regulation FD Disclosure), the report states that on December 6, 2021 Scilex Holding Company, a majority-owned subsidiary of Sorrento, issued a press release announcing the signing of a letter of intent for a potential business combination with Vickers Vantage Corp I, a Cayman Islands corporation (NASDAQ: VCKA). The press release is furnished as Exhibit 99.1. The report states that the information is furnished and is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Henry Ji signed on December 6, 2021.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event
reported): December 6, 2021

SORRENTO THERAPEUTICS, INC.

(Exact Name of Registrant as Specified
in its Charter)

Delaware | 001-36150 | 33-0344842
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.)

4955 Directors Place

San Diego , CA 92121

(Address of Principal Executive Offices)
(Zip Code)

Registrant’s telephone number,
including area code: ( 858 ) 203-4100

N/A

(Former Name, or Former Address, if Changed
Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol | Name of each exchange on which registered
Common Stock, $0.0001 par value | SRNE | The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01. Regulation FD Disclosure.

On December 6, 2021, Scilex Holding Company, a
majority-owned subsidiary of Sorrento Therapeutics, Inc., issued a press release announcing the signing of a letter of intent for a potential
business combination with Vickers Vantage Corp I, a Cayman Islands corporation (NASDAQ: VCKA). A copy of the press release is furnished
herewith as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this Item 7.01 and
Exhibit 99.1 furnished as part of Item 9.01 of this Current Report on Form 8-K is being furnished and shall not be deemed “filed”
for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject
to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other filing under
the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference to such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 | Press Release, dated December 6, 2021.
104 | Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SORRENTO THERAPEUTICS, INC.
Date: December 6, 2021 | By: | /s/ Henry Ji, Ph.D.
Name: Henry Ji, Ph.D.
Title: Chairman of the Board, President and Chief Executive Officer

File and source

File

SEC_SRNE_8-K_filed2021-12-06_0001104659-21-146598.htm

Size

25,225 bytes

SHA-256

00738423e1c1d932a7bf00c387aa8671f6ff3e817c8044cee9d6ee69756d9d7a

Our copy

SEC_SRNE_8-K_filed2021-12-06_0001104659-21-146598.htm

Original

www.sec.gov